Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Second Sight Medical Products — Investor Presentation (February 2016)
19 slides from Vivani Medical's investor presentation, Feb 23, 2016
Slide 1: Investor Presentation 2016
NASDAQ: EYES Investor Presentation 2016 NASDAQ: EYES
Slide 2: Forward Looking Statements
NASDAQ: EYES Forward Looking Statements This presentation contains certain forward - looking information about Second Sight that is intended to be covered by the safe harbor for "forward - looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward - loo
Slide 3: Leader in Restoring Vision through Technology
NASDAQ: EYES Leader in Restoring Vision through Technology 3 Leading Platform Technology for the Blind • First and only FDA - approved neurostimulation device for the blind on the market • 348 patents granted; 155 pending • 16+ years of R&D Significant Addressable Market • 8+ million people blind du
Slide 4: Targeting Large Addressable Market
NASDAQ: EYES Targeting Large Addressable Market Of the 39M people worldwide that are legally blind, 8M+ are due to untreatable causes 4 Treatable Causes 30.8M (78%) Untreatable Causes 8.2M (22%) Worldwide Patients Who Are Legally Blind RP 0.4M Other Untreatable Causes 5.8M AMD 2.0M 5.8 M Other Untre
Slide 5: Argus II – Restoring Useful Vision
NASDAQ: EYES 16+ years of R&D 170+ implants since 2002 Argus® II – Restoring Useful Vision Key Benefits: » Improved orientation and mobility » Enhanced connection to surroundings » Improved Quality of Life » Enhanced ability to perform daily activities 5 http://www.bloomberg.com/news/videos/2015 - 0
Slide 6: The Argus II Platform
NASDAQ: EYES 60 electrodes Argus II Platform Neurostimulation Technology Hermetic Package Smallest size & largest number of individually programmable electrodes Patented Electrode Material Enables Small Size Facilitates smaller & more concentrated electrodes in given area Long - Term Reliability Saf
Slide 7: Major Awards & Recognition
NASDAQ: EYES Major Awards & Recognition 7
Slide 8: Progress Since November 2014 IPO
NASDAQ: EYES Progress Since November 2014 IPO • NASDAQ IPO raises $32M • 18 implanting centers certified at year end • FY 2015: Expanded to 33 implanting centers • FY 2015: Completed 75 implants • Added MAC coverage in 10 states for a total of 16 states • Appointed Will McGuire as CEO • Entered into
Slide 9: Our Strategy
NASDAQ: EYES Our Strategy Grow Commercial Footprint & Expand Reimbursement Coverage Enhance Argus II Technology Enter AMD Market Expand into Direct Cortical Stimulation Build organizational foundation supporting operational excellence and sustained long - term growth Goal : 9
Slide 10: Growing Commercial Footprint
NASDAQ: EYES Growing Commercial Footprint • 33 centers of excellence worldwide • Direct sales: 9 field sales reps & clinical specialists • Distribution partners: Spain, Turkey, Saudi Arabia & Argentina • New markets under consideration in Asia/Pacific & Latin America North America 15 Centers ROW 18
Slide 11: Expanding Reimbursement Coverage
NASDAQ: EYES Expanding Reimbursement Coverage CMS Coverage 4 of 12 MAC Regions issued coverage policies (33% of U.S. population) 89% Pre - Authorizations approved by Medicare Advantage in 2015 24 Medicare Advantage or Private I nsurer Plans • approved case - by - case • $144K ASP in 2015 CMS Pricing
Slide 12: Enhancing Argus II Technology
NASDAQ: EYES Enhancing Argus II Technology Current Indication: • Bare or no light perception in RP patients in U.S. • Severe to profound vision loss from outer retinal degeneration in Europe External Hardware Upgrade • 25x VPU higher processing power Advanced Image Processing Software • Better defin
Slide 13: Entering AMD Market
NASDAQ: EYES Entering AMD Market • 5 subject clinical trial in the UK initiated June 2015 • 4 of 5 patients enrolled as of Dec. 31, 2015 • Patients to be evaluated over six month period to determine next steps and go forward strategy 13 Dry AMD Pilot Study Normal Vision Vison with Dry AMD Determine
Slide 14: Expanding into Direct Cortical Stimulation
NASDAQ: EYES Expanding into Direct Cortical Stimulation 14 Leverage existing Argus II technology Bypass the optic nerve and directly stimulate the visual cortex Fully active animal implants expected by Q1 2016 Begin clinical trials in 1H 2017 Restore vision to 5.8 million patients blinded by trauma
Slide 15: Patent Protection
NASDAQ: EYES Patent Protection Other challenges, 192 grants and applications Reliable long lived miniature electronics package, 92 grants and apps Safe and reliable flexible neural interface with many electrodes, 81 grants and apps Interconnect package to electrode array, 44 grants and apps Material
Slide 16: Competitive Landscape
NASDAQ: EYES Competitive Landscape Regulatory Approval In Market CE FDA ✔ ✖ ✖ ✖ ✖ ✖ ✖ ✖ ✖ ✖ ✖ ✖ Dominant industry position for the foreseeable future (Germany) (France) (Japan) (Israel) Therapeutic Approaches to Vision Loss • Significant first mover advantage with 5 + year lead time in the U.S. • Se
Slide 17: Select Financials
NASDAQ: EYES Select Financials (USD $ in Thousands) 9M 2015 9M 2014 FY 2014 FY 2013 Revenue $6,588 $1,878 $3,398 $1,565 Gross Profit 2,966 (259) (160) (4,064) Net L oss (14,545) (21,624) (35,201) (22,968) Non - GAAP Adjusted Net Loss* (12,394) (13,840) (19,401) (17,185) (USD $ in Thousands) Sep 30,
Slide 18: Investment Highlights
NASDAQ: EYES Investment Highlights • First mover advantage with leading Argus II platform technology to restore vision to the blind • Only U.S. FDA approved retinal prosthesis • 33 implanting centers & 170+ implants worldwide • Successful execution of reimbursement strategy in U.S. & Europe • Target
Slide 19: Investor Relations Contacts
NASDAQ: EYES Retail Investor Relations Matt Hayden Chairman MZ North America Direct: 949 - 259 - 4986 Matt.Hayden@mzgroup.us Second Sight Medical Products, Inc. 12744 San Fernando Road Suite 400 Sylmar, CA 91342 Main: 818 - 833 - 5000 www.secondsight.com Institutional Investor Relations Lisa Wilson
Second Sight Medical Products — Investor Presentation (February 2016) on 6ix